UBS Group’s Verona Pharma VRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-89,887
| Closed | -$9.59M | – | 11216 |
|
|
2025
Q3 | $9.59M | Sell |
89,887
-1,096,294
| -92% | -$114M | ﹤0.01% | 3332 |
|
|
2025
Q2 | $112M | Buy |
1,186,181
+923,327
| +351% | +$68.4M | 0.02% | 879 |
|
|
2025
Q1 | $16.7M | Sell |
262,854
-110,551
| -30% | -$6.61M | ﹤0.01% | 2533 |
|
|
2024
Q4 | $17.3M | Buy |
373,405
+238,837
| +177% | +$8.97M | ﹤0.01% | 2480 |
|
|
2024
Q3 | $3.87M | Buy |
134,568
+31,689
| +31% | +$780K | ﹤0.01% | 3343 |
|
|
2024
Q2 | $1.49M | Buy |
102,879
+101,044
| +5,506% | +$1.48M | ﹤0.01% | 4051 |
|
|
2024
Q1 | $29.5K | Sell |
1,835
-179
| -9% | -$3.1K | ﹤0.01% | 6747 |
|
|
2023
Q4 | $40K | Sell |
2,014
-1,323
| -40% | -$19.5K | ﹤0.01% | 6671 |
|
|
2023
Q3 | $54.4K | Buy |
3,337
+332
| +11% | +$6.39K | ﹤0.01% | 6239 |
|
|
2023
Q2 | $63.5K | Sell |
3,005
-2,427
| -45% | -$51.8K | ﹤0.01% | 6333 |
|
|
2023
Q1 | $109K | Buy |
5,432
+1,263
| +30% | +$27.3K | ﹤0.01% | 5851 |
|
|
2022
Q4 | $109K | Buy |
4,169
+3,391
| +436% | +$45.2K | ﹤0.01% | 6024 |
|
|
2022
Q3 | $8K | Buy |
+778
| New | +$6.56K | ﹤0.01% | 8755 |
|
|
2022
Q2 | – | Sell |
-655
| Closed | -$3K | – | 10997 |
|
|
2022
Q1 | $3K | Buy |
+655
| New | +$3.81K | ﹤0.01% | 9492 |
|
|
2021
Q4 | – | Sell |
-879
| Closed | -$5K | – | 10750 |
|
|
2021
Q3 | $5K | Buy |
+879
| New | +$5.12K | ﹤0.01% | 8562 |
|
|
2021
Q2 | – | Sell |
-1,407
| Closed | -$12K | – | 9859 |
|
|
2021
Q1 | $12K | Sell |
1,407
-316
| -18% | -$2.62K | ﹤0.01% | 7814 |
|
|
2020
Q4 | $12K | Buy |
1,723
+327
| +23% | +$2.21K | ﹤0.01% | 7362 |
|
|
2020
Q3 | $9K | Buy |
+1,396
| New | +$9.64K | ﹤0.01% | 6954 |
|
|
2020
Q2 | – | Sell |
-4,000
| Closed | -$16K | – | 8399 |
|
|
2020
Q1 | $16K | Sell |
4,000
-6,055
| -60% | -$33.2K | ﹤0.01% | 6648 |
|
|
2019
Q4 | $58K | Buy |
10,055
+8,940
| +802% | +$39K | ﹤0.01% | 6269 |
|
|
2019
Q3 | $5K | Sell |
1,115
-272
| -20% | -$1.22K | ﹤0.01% | 7492 |
|
|
2019
Q2 | $7K | Buy |
+1,387
| New | +$8.46K | ﹤0.01% | 7255 |
|
|
2019
Q1 | – | Sell |
-138
| Closed | -$1K | – | 8203 |
|
|
2018
Q4 | $1K | Buy |
+138
| New | +$1.57K | ﹤0.01% | 7920 |
|
|
2018
Q2 | – | Sell |
-703
| Closed | -$14K | – | 8282 |
|
|
2018
Q1 | $14K | Buy |
703
+702
| +70,200% | +$10.1K | ﹤0.01% | 6670 |
|
|
2017
Q4 | $0 | Buy |
+1
| New | +$13 | ﹤0.01% | 8125 |
|
Other funds holding VRNA
UBS Group's VRNA Position: Q4 2025 in Review
UBS Group sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 89,887 shares — an estimated $9.59M sold.
UBS Group first reported a position in VRNA in Q4 2017 and held it in 25 quarters. The position peaked at $112M in Q2 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.
- UBS Group reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
- UBS Group sold 89,887 Verona Pharma shares in Q4 2025, an estimated $9.59M.
- UBS Group first reported a position in Verona Pharma in Q4 2017 and held it in 25 quarters.
- UBS Group's Verona Pharma position peaked at $112M in Q2 2025.
- 1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.
Based on UBS Group's 13F filing for Q4 2025, filed 29 Jan 2026.